Precigen's PAPZIMEOS Sees 'Robust Uptake,' Q1 Revenue Expected to Top $18M
PGEN has more than doubled off its 52-week low of $1.11.
Summary
Precigen announced robust uptake for its new drug, PAPZIMEOS, for recurrent respiratory papillomatosis (RRP), with first-quarter 2026 revenue expected to exceed $18 million. This represents a significant increase from the $3.4 million in net product revenue reported for Q4 2025, signaling strong commercial momentum for the company's key product. The Centers for Medicare & Medicaid Services (CMS) also assigned a J-code to the therapy, effective April 1, 2026, which will streamline reimbursement and broaden patient access. This positive update indicates a successful transition for Precigen from an R&D-focused company to a product revenue-generating biotech, a critical development given its previously reported substantial net losses. Traders will be watching for confirmation of these revenue figures and further updates on PAPZIMEOS's market penetration and potential expansion into pediatric use and European markets.
At the time of this announcement, PGEN was trading at $4.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $1.11 to $5.47. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Access Newswire.